{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Hypersensitivity&page=13", "query": { "condition": "Drug Hypersensitivity", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 335, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Hypersensitivity&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Hypersensitivity&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T11:24:48.866Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00961233", "title": "Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Eosinophilic Esophagitis" ], "interventions": [ { "name": "inhaled/swallowed budesonide", "type": "DRUG" }, { "name": "viscous/swallowed budesonide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2009-10", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2012-11-06", "last_synced_at": "2026-10-26T11:24:48.866Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00961233" }, { "nct_id": "NCT02983630", "title": "Allergy Testing of Patients Labeled as Penicillin Allergic", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Drug Hypersensitivity" ], "interventions": [ { "name": "Penicillin allergy testing", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Albany Medical College", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2016-07", "completion_date": "2017-07-01", "has_results": false, "last_update_posted_date": "2018-01-09", "last_synced_at": "2026-10-26T11:24:48.866Z", "location_count": 1, "location_summary": "Albany, New York", "locations": [ { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02983630" }, { "nct_id": "NCT06271993", "title": "SPT for Sensitization of Collagen Dressing", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Allergy Skin", "Allergic Skin Reaction" ], "interventions": [ { "name": "ColActivePlus Collagen Matrix Dressing", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Covalon Technologies Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 27, "start_date": "2024-02-08", "completion_date": "2024-02-16", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-26T11:24:48.866Z", "location_count": 1, "location_summary": "Torrance, California", "locations": [ { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06271993" }, { "nct_id": "NCT00198458", "title": "Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Hypersensitivity" ], "interventions": [ { "name": "Vitrase", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch & Lomb Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2004-07", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2013-03-18", "last_synced_at": "2026-10-26T11:24:48.866Z", "location_count": 1, "location_summary": "Davis, California", "locations": [ { "city": "Davis", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00198458" }, { "nct_id": "NCT03860376", "title": "Ex Vivo Drug Sensitivity Testing and Mutation Profiling", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Refractory Childhood Acute Lymphoblastic Leukemia", "Refractory Childhood Hodgkin Lymphoma", "Refractory Childhood Malignant Germ Cell Neoplasm", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Brainstem Glioma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Gliosarcoma", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive" ], "interventions": [], "intervention_types": [], "sponsor": "Florida International University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Day to 21 Years" }, "enrollment_count": 25, "start_date": "2019-02-21", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2023-05-10", "last_synced_at": "2026-10-26T11:24:48.866Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03860376" }, { "nct_id": "NCT06406114", "title": "Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Drug Allergy", "Cephalosporin Allergy", "Drug Hypersensitivity", "Antibiotic Allergy", "Beta Lactam Adverse Reaction", "Drug-Induced Anaphylaxis", "Cephalosporin Reaction" ], "interventions": [ { "name": "Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing", "type": "DRUG" }, { "name": "Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge", "type": "DRUG" }, { "name": "Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge", "type": "DRUG" }, { "name": "Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge", "type": "DRUG" }, { "name": "Amoxicillin double-blind placebo-controlled drug challenge", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 300, "start_date": "2025-05-05", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-26T11:24:48.866Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06406114" }, { "nct_id": "NCT06686797", "title": "A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-08049820", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 71, "start_date": "2024-11-27", "completion_date": "2026-02-23", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-26T11:24:48.866Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06686797" }, { "nct_id": "NCT05111262", "title": "Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Asthma", "Nonadherence, Medication" ], "interventions": [ { "name": "Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2021-12-16", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-26T11:24:48.866Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05111262" }, { "nct_id": "NCT06673654", "title": "A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Ruxolitinib Topical Cream 1.5%", "type": "DRUG" }, { "name": "OPZELURA (Ruxolitinib) Cream", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 476, "start_date": "2023-08-11", "completion_date": "2024-09-23", "has_results": false, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-10-26T11:24:48.866Z", "location_count": 1, "location_summary": "Hawthorne, New York", "locations": [ { "city": "Hawthorne", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06673654" }, { "nct_id": "NCT03556592", "title": "Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Caffeine", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Metoprolol", "type": "DRUG" }, { "name": "Midazolam Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-08-13", "completion_date": "2020-06-20", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-10-26T11:24:48.866Z", "location_count": 9, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Doral", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03556592" } ] }